Quality of Life of Chronic Hepatitis C Patients Receiving Sovaldi Treatment Regimen at Sharq Almadina Hospital in Alexandria

Abstract

Background: Hepatitis C virus (HCV) infection is a worldwide public health problem, affecting about 3% of the world's population. The introduction of sofosbuvir (Sovaldi) markedly changed therapeutic outcomes. The assessment of HRQoL in HCV patients under treatment might help to better understand the effect of treatment on the patient's quality of life. Aim: The study was conducted to assess the quality of life of chronic hepatitis C patients receiving Sovaldi at the outpatient hepatology clinic in Sharq Almadina hospital. Patients and Methods: A cross-sectional survey was conducted among chronic hepatitis C patients receiving Sovaldi treatment regimen for at least 3 months. Data was collected from the studied CHCV patients using face-to-face interviews including personal & sociodemographic characteristics, The chronic liver disease questionnaire (CLDQ) to assess health-related quality of life, and the translated Arabic version of the short-form (SF 36) generic quality of life questionnaire. In addition, reviewing the medical records of studied CHCV patients to collect data about their laboratory findings was done. Results: More than two-thirds of studied patients (69.1%) discovered the disease during the National Egyptian Campaign. The overall median value of SF-36Q items was 53.19 indicating a poor HRQoL. There were significant positive correlations between the majority of SF-36Q individual domain scores and that for CLDQ P <0.001 as well as the total scores. Conclusions: There were significant positive correlations between the majority of SF-36Q individual domain scores and that for CLDQ as well as the total scores.